This article was originally published in The Rose Sheet
Executive SummaryThe Scientific Advisory Committee on Alternative Toxicological Methods recommends as a high priority the further evaluation of three methods designed to replace or refine animal use in toxicology testing. The tests were discussed at a Nov. 30 meeting in Research Triangle Park, NC. The first test is the MCF-7 estrogenic activity cell proliferation assay for cross-laboratory validation studies, which assesses the potential endocrine disruptor activity of a substance. The second nomination goes to the BALB/c 3T3 mouse fibroblast neural red uptake test method for predicting the starting doses of chemical mixtures for acute oral toxicity testing. The third test up for further evaluation is the optimal corneal holder and vehicle for bovine corneal opacity and permeability, which is used to identify potential ocular corrosives. The studies are currently undergoing pre-screening by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods and the Interagency Coordinating Committee on the Validation of Alternative Methods...
You may also be interested in...
In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.